The role of microRNAs (miRNA) in many diseases, including chronic hepatitis, represents an interesting research field. The current work aimed to study the effect of combination therapy (pegylated interferon alpha-2b plus ribavirin) on microRNA-128 (miR-128) and microRNA-296 (miR-296-5p) expression in patients with chronic hepatitis C. Also, we aimed to investigate the potential value of both types of microRNAs in differentiation between responders and nonresponders either in the pre-treatment or post-treatment groups. Sixteen patients with chronic hepatitis C were compared to 10 healthy, age and sex matched controls. Venous blood samples were withdrawn before initiation of combination therapy and 12 weeks later and qPCR was used for gene expression assays. Comparison of pre-treatment group to the control group showed significant miR-128 down-regulation, while miR-296-5p showed a non-significant downregulation. Regarding post-treatment group, there was non-significant upregulation of miR-128, while miR-296-5p was significantly downregulated compared to either pre-treatment group or the control group. Comparative studies of miR-128 and miR-296-5p in responders versus nonresponders showed non-significant fold change either in the pre-or post-treatment groups. It could be concluded that chronic hepatitis C as well as the combination therapy modulate miR-128/296 expression. Until now, miRNAs studied were not useful indicators to differentiate between responders and non-responders to combination therapy either in pre-or post-treatment group. 
Introduction
Egypt has the highest prevalence of hepatitis C in the world and chronic hepatitis C viral infection (HCV) is the main cause of liver cirrhosis and cancer. HCV isolates, based on genetic differences, can be classified into six genotypes (1-6) where genotype 4 predominates in Egypt (1) . 
Early virological response (EVR

Sampling:
Venous blood sample (8.5 ml) was withdrawn from each subject and divided into four parts, after signing a written informed consent. The first part (2.0 ml) was collected into ethylene diamine tetra- The manufacturers' instructions were followed throughout all steps.
Molecular Analysis of Gene Expression of Circulating miR-128 and miR-296-5p:
The RNeasy® Protect Animal Blood kit (Qiagen, 
Statistical analysis:
The collected data were computed and statistically analyzed using SPSS program version 16 software for windows (SPSS Inc, Chicago, ILL Company).
Independent and dependent variables were expressed as mean ± SD, median and range. Data were compared using Wilcoxon -Mann-Whitney for non-parametric results. p value <0.05 was considered significant.
Results
The demographic data, clinical, biochemical and pathological laboratory findings of the studied groups are summarized in Tables (1 and 2 ).
Regarding miR-128, our results showed nonsignificant upregulation in the post-treatment patients as compared to either controls or pretreatment patients (p>0.05 each), Table ( 3).
However, comparison of pre-treatment group with the control group revealed that it was significantly downregulated (p<0.05), Table ( 3).
Furthermore, the expression of miR-296-5p in the post-treatment group was decreased compared to that of the control group and the pre-treatment with significant statistical difference (p<0.05 each). On the other hand, miR-296-5p in the pretreatment group showed non-significant downregulation as compared to the control group (p>0.05), Table ( 3).
Finally, comparison of miR128/296 between responders and non-responders, revealed nonsignificant differences in pre-and post-treatment groups, figure (1). The current work aimed to study the effect of combination (pegIFN/RBV) therapy on microRNA-128 and microRNA-296 in patients with chronic hepatitis C. Also, to verify that; these 2 types of microRNAs might be useful to differentiate between responders and non-responders either in the pre-treatment or post-treatment group.
Our results showed that miR-128 and miR-296-5p
were expressed in whole blood collected from healthy individuals (Table: 3). A previous study reported that miRNAs were expressed in peripheral blood mononuclear cells (PBMNCs) from healthy volunteers and HCV patients (4). In addition, it was found that miRNAs were expressed in PBMNCs from healthy subjects (29).
MiR-128 showed significant downregulation while miR-296-5p showed non-significant decrease of expression in the pre-treatment group compared to the control group (Table: 3). 
Secondly, HCV inhibits IRF-3 a protein that induces IFN gene transcription (34).
Finally, HCV inhibits protein kinase R (PKR) due
to sequence similarity between HCV envelope (E2)
protein and phosphorylation sites of PKR and its target, the translation initiation factor (eIF2α).
Thus, E2 blocks PKR inhibitory effect on protein synthesis and cell growth (35) .
Type I IFNs regulate the host miRNAs which inhibits HCV replication and infectivity. Clearly, endogenous INF-α when decreases, leads to subsequent inhibition of interferon stimulated genes transcription including the genes coding for miRNAs (36) .
The current data are in accordance with a previous report that showed modulation of 3 miRNAs including miR-128a which showed downregulation in 3 HCV replicon clones (37) . Moreover, they predicted the gene targets of the 3 miRNAs.
Interestingly, those targets may be involved in pathways to sustain HCV replication and / or to control the antiviral response by the virus itself.
However, contradictory to our results, Scagnolari and colleagues reported that expression of miR-128
and miR-296-5p showed non-significant increase in the pre-treatment compared to the control group (4). A More recent study, revealed a significant increase in miR-128 and miR-296-5p in the pretreatment compared to the control group (29). Such controversies may be attributed to different sample types and the small sample size in our study.
In addition, our results showed non-significant upregulation of miR-128 while significant dowregulation of miR-296-5p in the post treatment compared either with the pre-treatment group or with the control group (Table: 3).
The results of miR-128 were in agreement with two former studies, while those of miR-296-5p were contradictory to both of them (4,29).
Scagnolri and his group (4), separated PBMNCs from CHC patients before and 12 hours after initiating pegylated interferon alpha therapy. They noticed significant increase in miR-128 and miR-296-5p in the post treatment compared with pretreatment group. They attributed such upregulation to induction by interferon alpha (4,29). To our mind, blood samples were taken 12 weeks after initiation of combination therapy in this work which may explain the opposing results of miR-
296.
Furthermore, such contradiction might be attributed to the viral ability to exert inhibitory effect against interferon induction and the function of its effector molecules (38) , and the ability of HCV to produce infinite genetic variants adds to the resistance mechanisms against interferon treatment (39) .
Comparative studies of miR-128 and miR-296-5p
in responders versus non-responders showed non- 
